Synageva BioPharma (GEVA)
Add to Watchlists Create an AlertGEVA Key Stats
| Income Statement | |
| Revenue TTM | 17.68M |
| Revenue Quarterly YoY Growth | 113.5% |
| EPS Diluted TTM | -2.074 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -50.08M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -283.0% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 1.099B |
| Enterprise Value | 879.69M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 4.773 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | |
| Free Cash Flow | |
| Return on Equity | |
GEVA News
- FDA Designation for Synageva Candidate - Analyst Blog Zacks 5:20 PM
- Synageva's Sebelipase Alfa Receives Breakthrough Therapy Designation for Early O... May 20
- 3 Horrendous Health-Care Stocks This Week Fool May 18
- Synageva BioPharma™ Joins the International MPS Network in Support of MPS Awaren... May 15
- Nasdaq stocks posting largest percentage decreases AP May 14
- Nasdaq stocks posting largest percentage decreases May 13
- UPDATE: J.P. Morgan Downgrades Synageva BioPharma to Neutral on Challenges Ahead Benzinga May 10
- Synageva BioPharma Corp Enters Oversold Territory (GEVA) May 10
- Synageva downgraded to Neutral from Overweight at JPMorgan May 10
- A Peek Into The Market Before The Trading Starts Benzinga May 10
GEVA Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Synageva BioPharma is up 2.55% over the last year vs S&P 500 Total Return up 28.68%, Infinity Pharmaceuticals up 88.85%, and Imprimis Pharmaceuticals up 126.5%.
GEVA Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these GEVA related companies
Pro Ratings for GEVA
Pro Report PDF for GEVA
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download GEVA Pro Report PDF
Pro Strategies Featuring GEVA
Did Synageva BioPharma make it into our Pro Portfolio Strategies?
GEVA Profile
Sector: Healthcare
Industry: Biotechnology
Other GEVA Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| GEVA | 40.29 | +0.77 | +1.95% | 1.099B |
